TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24284856
Drug: Transdermal VALE-ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal VALE-ibuprofen
Study: 16126290
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen (4 L/min)
Study: 14571151
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (paroxetine)
Study: 14571151
Drug: Serotonin-noradrenaline reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin-noradrenaline reuptake inhibitor (venlafaxine)
Study: 14571151
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (absence of previous therapies, moderate baseline severity of obsessive-compulsive symptoms, low Hamilton Depressive Rating Scale scores)
Study: 1982059
Drug: Oxprenolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (80 mg/day)
Study: 233458
Drug: Intrapleural administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of Corynebacterium parvum (7 mg)
Study: 30309816
Drug: Rufinamide (≤45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide (≤45 mg/kg/day)
Study: 26660938
Drug: Visomitin eye
Normalized name: sisomicin
DrugBank: Sisomicin (DB12604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visomitin eye drops, self-administered three times daily (TID) for 6 weeks
Study: 26660938
Drug: Placebo, self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, self-administered three times daily (TID) for 6 weeks
Study: 23260618
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation (30 min daily for 7 days)
Study: 21189270
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (45mg/kg/day for 3 days)
Study: 10845809
Drug: Day 1
Normalized name: New Day 1.5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 + 8 schedule (5FU and CTX 500mg/m2 day 1, epirubicin 40 mg/m2 day 1 and 8)
Study: 10845809
Drug: Day 1
Normalized name: New Day 1.5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 schedule (5FU, CTX 500 mg/m2 and epirubicin 80 mg/m2 day 1)
Study: 8271802
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment focused on drinking reduction techniques
Study: 2961316
Drug: Regular chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular chloroquine (10 mg base kg‐1)
Study: 2961316
Drug: Enteric-coated chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated chloroquine (10 mg base kg‐1)
Study: 2961316
Drug: Amodiaquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (10 mg base kg‐1)
Study: 2961316
Drug: Enteric-coated ferrous
Normalized name: ferrous sulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated ferrous sulphate (300 mg tablet)
Study: 26686313
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg oral daily for 5 years)
Study: 26686313
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg oral daily for 5 years)
Study: 4047104
Drug: Combined estrogen‐progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen‐progestogen (high-dose: 4 mg of estradiol)
Study: 4047104
Drug: Combined estrogen‐progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen‐progestogen (other doses)
Study: 20540639
Drug: Keto acids‐supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keto acids‐supplemented low‐protein diet (sLP: 0.6‐0.8 g/kg IBW/d + 0.12 g/kg IBW/d of keto acids, n = 12)
Study: 20540639
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LP: 0.6‐0.8 g/kg IBW/d, n = 13)
Study: 20540639
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (HP: 1.0‐1.2 g/kg IBW/d, n = 14)
Study: 16673835
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy plus education intervention
Study: 8678510
Drug: Bolus i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus i.v. infusion of 5‐FU
Study: 8678510
Drug: Protracted i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted i.v. infusion of 5‐FU
Study: 8678510
Drug: Tomudex (pure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomudex (pure TS inhibitor)
Study: 8678510
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low‐dose cisplatin and 5‐FU
Study: 8678510
Drug: New dihydropyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dihydropyrimidine dehydrogenase inhibitors
Study: 8678510
Drug: New TS
Approvals — FDA: no, EMA: no, PMDA: no
Description: New TS inhibitors
Study: 1905621
Drug: ponalrestat 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ponalrestat 600 mg once daily for 6 weeks
Study: 29986562
Drug: Standard antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotics (B group)
Study: 29986562
Drug: Prolonged antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antibiotics (C group)
Study: 29986562
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (A group)
Study: 29986562
Drug: Standard antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotics (E group)
Study: 29986562
Drug: Prolonged antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antibiotics (F group)
Study: 29986562
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (D group)
Study: 27470088
Drug: Bromelain (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain (500 mg/day)
Study: 22211833
Drug: 2 units
Normalized name: Afrezza, 12 units inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 units FFP plus 2 g fibrinogen concentrate
Study: 16091379
Drug: Irbesartan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (1 mg/kg body weight) daily for 12 weeks
Study: 12044433
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of protamine every 100 IU of heparin (Group A)
Study: 12044433
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of protamine every 100 IU of heparin (Group B)
Study: 10460567
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml bupivacaine 0.125% with epinephrine 1/800 000 (group B)
Study: 10460567
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline (group S)
Study: 7637642
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 100 mg intramuscularly each month for 6 months
Study: 7637642
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate treatment
Study: 2576665
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg three times a day for 4 weeks
Study: 2576665
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg once a day for 4 weeks
Study: 31852672
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day prednisone (maintenance)
Study: 31852672
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of 5 mg/day prednisone
Study: 29955151
Drug: SSRI sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI sertraline
Study: 25134887
Drug: English only
Approvals — FDA: no, EMA: no, PMDA: no
Description: English only (EO) treatment
Study: 25134887
Drug: Bilingual skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilingual skills in Spanish and English (BI) treatment
Study: 25134887
Drug: Nonlinguistic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonlinguistic cognitive processing (NCP) treatment
Study: 22290266
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor occupancy >77%
Study: 22290266
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor occupancy >80%
Study: 8633944
Drug: Prophylactic high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic high-dose aprotinin (group 1)
Study: 8633944
Drug: Postoperative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative low-dose aprotinin (group 2)
Study: 1444728
Drug: Amantadine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (300 mg/d)
Study: 6534186
Drug: Routine, eclectic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine, eclectic, 28-d inpatient alcoholism treatment program
Study: 31607468
Drug: WHO's recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO's recommended regimen (daily UNIMMAP containing 60 mg iron)
Study: 31607468
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg screen-and-treat approach (daily UNIMMAP containing 60 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Study: 31607468
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg screen-and-treat approach (daily UNIMMAP containing 30 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Study: 31607468
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg screen-and-treat approach
Study: 31607468
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg screen-and-treat approach
Study: 20642296
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (Lactobacillus acidophilus DDS‐1, Bifidobacterium lactis UABLA‐12 with fructo‐oligosaccharide at a dosage of 5 billion colony‐forming units twice daily for 8 weeks)
Study: 15986013
Drug: New immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: New immunosuppressive agents
Study: 15986013
Drug: Various combination
Normalized name: various combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various combination protocols
Study: 7780071
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (hydrated group)
Study: 7780071
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (nonhydrated group)
Study: 31566320
Drug: Orchid drug-coated
Normalized name: Orchis mascula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchid drug-coated balloon (DCB)
Study: 21915733
Drug: Cefotetan disodium
Normalized name: Cefotetan Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan disodium (all doses)
Study: 18324419
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal vaccine (PV) in group 1 (nephrotic children on high-dose prednisone)
Study: 18324419
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal vaccine (PV) in group 2 (patients in remission)
Study: 10545309
Drug: beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker therapy (atenolol or metoprolol)
Study: 8669218
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylnaltrexone IV at the end of surgery
Study: 22333107
Drug: Hyperbaric air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric air therapy (Control)
Study: 19617208
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G‐CSF) at a dosage of 1 microg/kg/day starting on the sixth day after ovulation.
Study: 15128683
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medications (PIMs) prescribed to seniors
Study: 15128683
Drug: Oxybutynin prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin prescriptions
Study: 8067217
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with adrenaline (5 ug.ml‐1)
Study: 8067217
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with adrenaline (5 ug.ml‐1)
Study: 8067217
Drug: Ropivacaine (plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (plain solutions)
Study: 8067217
Drug: Bupivacaine (plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (plain solutions)
Study: 31301451
Drug: Fecal Microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal Microbiota Transplantation (FMT) capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8)
Study: 25616438
Drug: n-3 FA
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA supplementation (1.7 g DHA and 0.6 g EPA daily for 6 months)
Study: 24169736
Drug: Dance-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance-based exercise therapy (1 hour)
Study: 21958585
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg, 2 single intravenous injections, 28 days apart)
Study: 18986283
Drug: Appropriate antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate antimicrobial treatment for mild CAP
Study: 18986283
Drug: Ineffective therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineffective therapies or no therapy
Study: 11449032
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of methylphenidate (MPH)
Study: 9554249
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 6-10, and 0.70 mg norethindrone only on days 11-19. Placebo on days 1-5 and 20-28.
Study: 9554249
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Combination of 50 micrograms ethinyl estradiol and 1 mg norethindrone per tablet on days 8-12, and 0.70 mg norethindrone only on days 13-21. Placebo on days 1-7 and 22-28.
Study: 2977393
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg amlodipine
Study: 2977393
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amlodipine
Study: 29273269
Drug: Extended-pulsed fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1-5, then once daily on alternate days on days 7-25)
Study: 29273269
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg oral capsules, four times daily on days 1-10)
Study: 26649741
Drug: Ceftazidime 2000
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2000 mg and Avibactam 500 mg
Study: 23169194
Drug: Verified prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verified prescription using probe‐microphone measurement
Study: 23169194
Drug: Verified prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verified prescription
Study: 20089954
Drug: Oral fingolimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fingolimod 1.25 mg
Study: 20089954
Drug: Oral fingolimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fingolimod 0.5 mg
Study: 20167591
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a
Study: 18931224
Drug: High-dose antithrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antithrombin (30,000 IU IV over 4 days)
Study: 18931224
Drug: High-dose antithrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antithrombin
Study: 11495875
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of intrathecal ropivacaine (group R)
Study: 11495875
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg ropivacaine with 10 microg of sufentanil (group RS)
Study: 9759744
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment (omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily for 1 week)
Study: 9759744
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (omeprazole with placebo antibiotics)
Study: 28473006
Drug: Watermemories Swimming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermemories Swimming Club aquatic exercise program (12 weeks, twice weekly)
Study: 20926529
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (0.64 mg/d)
Study: 9146855
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (600 micrograms)
Study: 7711007
Drug: Glucose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (100 g in 400 ml) administered 30 min before tests
Study: 7711007
Drug: Water (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (equal volume to glucose) administered 30 min before tests
Study: 30538005
Drug: G:G genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: G:G genotype
Study: 25439692
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg once-daily
Study: 23044290
Drug: Anisodamine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anisodamine infusion at a rate of 0.2 µg×kg(‐1)×min(‐1) from 12 hours before to 12 hours after coronary angiography or angioplasty
Study: 23044290
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride infusion (control group)
Study: 23044290
Drug: Anisodamine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anisodamine infusion
Study: 18839224
Drug: MESNA (Uromixetan
Approvals — FDA: no, EMA: no, PMDA: no
Description: MESNA (Uromixetan MESNA, 50 mg/ml)
Study: 14500050
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (initially allocated in a 1:1 ratio)
Study: 14500050
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (initially allocated in a 1:1 ratio)
Study: 14500050
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential design
Study: 6701925
Drug: Reduced-dose irradiation
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose irradiation and subsequent simultaneous combination of polychemotherapy and irradiation
Study: 12474066
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (330 mL daily for 8 weeks)
Study: 9841956
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate solution (0.3 g x kg‐1 body mass)
Study: 7806684
Drug: Haloperidol 20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 20 mg
Study: 7806684
Drug: Haloperidol 30
Normalized name: Haloperidol 300 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 30 mg
Study: 2760092
Drug: Repair and
Normalized name: Pantene Repair And Protect Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repair and augmentation of the anterior cruciate ligament with a strip of the iliotibial band
Study: 28505233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone (DEX), ondansetron (OND), and droperidol (DRO) (Group B)
Study: 28505233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone (DEX) and ondansetron (OND) (Group A)
Study: 22433304
Drug: ETV 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV 1.0 mg/d monotherapy
Study: 22433304
Drug: ETV +
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETV + ADV 10 mg/d
Study: 19454403
Drug: SGS (structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGS (structured diabetes teaching and treatment programme)
Study: 12601511
Drug: Pelvicol( trademark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvicol( trademark ) implant
Study: 8724378
Drug: Hypertonic glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic glucose solution (Group I)
Study: 3927062
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II - Specially formulated amino acid solution with glucose and fructose
Study: 29317275
Drug: Dose increases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (DIS1 group)